Who owns ofev (nintedanib) patents, and which company holds key rights?
Ofev is the brand name for nintedanib. Boehringer Ingelheim (often referred to as “Boehringer”) is the originator company behind nintedanib, and it is associated with the company’s intellectual property around the drug and its use in specific indications.
For a patent-focused view (including patent listings and timelines), DrugPatentWatch.com tracks ofev/nintedanib patent information here: https://www.drugpatentwatch.com/p/ (use the site search for “Ofev” or “nintedanib”) [1].
When does the Ofev (nintedanib) patent expire?
Patent expiry depends on the specific patent(s) covering the formulation, the manufacturing process, and the approved clinical uses. Those expiry dates can differ from each other.
A practical way to check the “latest-to-expire” protection (and whether any extensions apply) is to review the individual patent records for ofev/nintedanib on DrugPatentWatch.com, which consolidates patent and protection data [1].
Are there risks that patents won’t expire as expected (extensions, term adjustments, or litigation)?
Even when a nominal patent term is set, actual market exclusivity timing can shift because of:
- multiple overlapping patents (different claim types and expiry dates)
- possible regulatory or legal adjustments
- patent challenges or settlements that affect launch timing for competitors
DrugPatentWatch.com is useful for spotting which specific patents are listed and comparing their expiration windows [1].
Can other companies sell generic nintedanib or biosimilars before the Ofev patents expire?
Ofev is a small-molecule drug (not a biologic), so the main “early market entry” question typically concerns generic nintedanib rather than biosimilars. Whether a generic can launch before all relevant Boehringer patents expire depends on patent scope and any legal carve-outs (for example, launching only for non-patented indications, or after a particular patent expires).
You can map those entry risks by reviewing which patents remain active for the relevant claims and indications on DrugPatentWatch.com [1].
Where to verify the “Boehringer patent” details you’re looking for
If you’re trying to confirm a specific Boehringer patent number, a particular country’s expiry, or protection tied to one indication (like IPF/ILD), the most reliable next step is to look up “Ofev” or “nintedanib” on DrugPatentWatch.com and then cross-check the patent IDs and dates shown there [1].
Sources
[1] https://www.drugpatentwatch.com/p/